A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

BACKGROUND Despite the use of antiplatelet agents, usually aspirin, in patients who have had an ischemic stroke, there is still a substantial rate of recurrence. Therefore, we investigated whether warfarin, which is effective and superior to aspirin in the prevention of cardiogenic embolism, would also prove superior in the prevention of recurrent ischemic stroke in patients with a prior noncardioembolic ischemic stroke. METHODS In a multicenter, double-blind, randomized trial, we compared the effect of warfarin (at a dose adjusted to produce an international normalized ratio of 1.4 to 2.8) and that of aspirin (325 mg per day) on the combined primary end point of recurrent ischemic stroke or death from any cause within two years. RESULTS The two randomized study groups were similar with respect to base-line risk factors. In the intention-to-treat analysis, no significant differences were found between the treatment groups in any of the outcomes measured. The primary end point of death or recurrent ischemic stroke was reached by 196 of 1103 patients assigned to warfarin (17.8 percent) and 176 of 1103 assigned to aspirin (16.0 percent; P=0.25; hazard ratio comparing warfarin with aspirin, 1.13; 95 percent confidence interval, 0.92 to 1.38). The rates of major hemorrhage were low (2.22 per 100 patient-years in the warfarin group and 1.49 per 100 patient-years in the aspirin group). Also, there were no significant treatment-related differences in the frequency of or time to the primary end point or major hemorrhage according to the cause of the initial stroke (1237 patients had had previous small-vessel or lacunar infarcts, 576 had had cryptogenic infarcts, and 259 had had infarcts designated as due to severe stenosis or occlusion of a large artery). CONCLUSIONS Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage. Consequently, we regard both warfarin and aspirin as reasonable therapeutic alternatives.

[1]  S. Solymoss,et al.  Aspirin, Warfarin, or the Combination for Secondary Prevention of Coronary Events in Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Surgery , 2001, Circulation.

[2]  C. Legnani,et al.  Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding , 2001, Thrombosis and Haemostasis.

[3]  R. Sacco,et al.  Antithrombotic and thrombolytic therapy for ischemic stroke. , 2001, Chest.

[4]  P A Wolf,et al.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.

[5]  J. Cleland,et al.  Clinical trials update: IMPROVEMENT‐HF, COPERNICUS, MUSTIC, ASPECT‐II, APRICOT and HEART , 2000, European journal of heart failure.

[6]  L. Goldstein,et al.  Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke , 2000, Stroke.

[7]  D. Singer,et al.  Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. , 2000, Circulation.

[8]  W M O'Fallon,et al.  Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. , 2000, Stroke.

[9]  T. Yamaguchi.  Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. , 2000, Stroke.

[10]  J. Gorter,et al.  Major bleeding during anticoagulation after cerebral ischemia , 1999, Neurology.

[11]  W. Feinberg,et al.  Clinically significant differences in the International Normalized Ratio measured with reagents of different sensitivities. SPAF Investigators. Stroke Prevention in Atrial Fibrillation. , 1999, Blood Coagulation and Fibrinolysis.

[12]  P. Petersen,et al.  Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. , 1999, Archives of internal medicine.

[13]  Joseph P. Broderick,et al.  Effects of tissue plasminogen activator for acute ischemic stroke at one year , 1999 .

[14]  Masahiro Kokai,et al.  Synapse alteration in hippocampal CA3 field following entorhinal cortex lesion , 1997, Journal of the Neurological Sciences.

[15]  M. Hennerici,et al.  The Feasibility of a Collaborative Double-Blind Study Using an Anticoagulant , 1997 .

[16]  P. Karanjia,et al.  Accuracy of initial stroke subtype diagnosis in the TOAST study , 1995, Neurology.

[17]  A. Algra,et al.  Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[18]  G. Hankey,et al.  Validation of a clinical classification for subtypes of acute cerebral infarction. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[19]  R. Sacco,et al.  Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community , 1994, Neurology.

[20]  P. Horner,et al.  Diarrhoea associated with Clostridium difficile in AIDS patients receiving rifabutin , 1994, The Lancet.

[21]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[22]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[23]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[24]  V. Fidler,et al.  IMPROVED PRIMARY RENAL ALLOGRAFT SURVIVAL ON CYCLOSPORIN LIMITED TO WOMEN WITH PREVIOUS PREGNANCIES , 1989, The Lancet.

[25]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[26]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[27]  Daniel B Hier,et al.  The Stroke Data Bank: design, methods, and baseline characteristics. , 1988, Stroke.

[28]  P. Sandercock,et al.  IS A CONTROLLED TRIAL OF LONG-TERM ORAL ANTICOAGULANTS IN PATIENTS WITH STROKE AND NON-RHEUMATIC ATRIAL FIBRILLATION WORTHWHILE? , 1986, The Lancet.

[29]  D. Siegmund.  Examples of Repeated Significance Tests , 1985 .

[30]  P. Touboul,et al.  "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. , 1983, Stroke.

[31]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .